HYML-122 / Tarapeutics Science, Youyuan Pharma - LARVOL DELTA

Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease. (PubMed, Int Immunopharmacol) - "In addition, HYML-122 is highly enriched in the intestinal tract, and significantly improve Dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats and dextran sulfate sodium (DSS)-induced colitis in mice. In conclusion, this study presented HYML-122 is a promising RIPK2 inhibitor with potential for further drug development for the treatment of IBD."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • FLT3 • NLRC5 • RIPK2

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=18 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Jun 2024 ➔ Jun 2026 | Trial primary completion date: Mar 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=18 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Mar 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Dec 2022 ➔ Jun 2024 | Trial primary completion date: Dec 2022 ➔ Mar 2024

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=18 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Dec 2022 ➔ Jun 2024 | Trial primary completion date: Dec 2022 ➔ Mar 2024

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3